Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2026 07:00 ET | Source: Relay Therapeutics, Inc.

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib...
January 20, 2026 12:00 ET | Source: ALSTOM SA

ALSTOM S.A: Alstom’s third quarter 2025/26: Record orders, Reaching €100bn backlog, FY 2025/26 outlook confirmed

Outstanding commercial momentum driving backlog to above €100bn Order intake of €9.6 billion in Q3 and €20.0 billion in the first 9 monthsBook-to-bill ratio1 of 1.4 for the Group and 1.8 for Rolling...
January 20, 2026 12:00 ET | Source: ALSTOM SA

ALSTOM S.A : Troisième trimestre de l’exercice fiscal 2025/26 d’Alstom : Performance commerciale record, le carnet de commandes atteint 100 milliards d’euros, perspectives 2025/26 confirmées

Une dynamique commerciale exceptionnelle porte le carnet de commandes au-delà de 100 milliards d’euros Commandes reçues au T3 à 9,6 milliards d’euros et 20,0 milliards d’euros pour les 9 moisRatio...
January 12, 2026 08:00 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental...
January 09, 2026 08:00 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer

CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for...
January 07, 2026 08:01 ET | Source: Vaxxas Pty Ltd

Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO

BRISBANE, Australia and CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive...
January 05, 2026 16:01 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Cyclerion & Medsteer entered a strategic agreement to enable the integration of Medsteer's technology and know-how into CYC-126.
December 22, 2025 08:00 ET | Source: Sinaptica Therapeutics

Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy

CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Sinaptica Therapeutics, a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat...
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week...
December 02, 2025 08:30 ET | Source: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...